FOR SALE: Pharmaceutical Plant Liquidation

Published: 15-Feb-2021
Manufacturing Hi Tech Manufacturing Estates & Facilities Pharmaceutical

Register here to be kept inform of all update concerning the AVARA Project - complete contents of modern 100 acre pharmaceutical facility - API and intermediate large scale manufacturing equipment (assets formerly owned by Astra Zeneca/Avara). The auction ends on 28 February.

Assets formerly owned by ASTRAZENECA / AVARA

Complete Contents of Modern 100 Acre Large Scale API Production & Development Facility Nearby Bristol, UK

Site Capabilities

Five Large-Scale cGMP API PLANTS

  • Large volume commercial manufacture of intermediates & APIs
  • 6m3 to 10m3 reactor capacity
  • Pressure filter, conical and centrifuge drying
  • High hazard chemistry
  • Synthesis
  • Purification
  • Storage

Two Large-Scale Milling Facilities

  • Two Hosakawa mills, 315 UPZ and associated equipment
  • Matcon bin charging

CGMP Large-Scale Laboratory

  • 10 L to 100 L reactor capacity
  • Chlorination with POCl3
  • Oxidation with peroxide and hypochlorite
  • Grignard reagents
  • Metal catalysts
  • Formulation
  • Cryogenic reactions

For more information, REGISTER HERE

  • Companies:
  • Maynards
See more

You may also like

Manufacturing

Maynards to manage asset dispersal at former Avonmouth pharma site

Read more
Recently the company completed the dispersal of the complete contents of Recipharm’s Ashton-under-Lyne pharmaceutical manufacturing facility

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Automate LC purification & high-purity compound recovery with UFPLC The purification instrument allows manufacturers to extract high-purity compounds in a shorter timeframe
  4. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Maynards to manage asset dispersal at former Avonmouth pharma site

Recently the company completed the dispersal of the complete contents of Recipharm’s Ashton-under-Lyne pharmaceutical manufacturing facility
Manufacturing

For easy transition from glass to plastic accessories - BOLA components with GL threads

The GL thread is the most common thread on lab equipment made of glass. Available from Labtex in the UK, BOLA offers a modular construction system with many different components with GL threads
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Manufacturing

Optimising RNA production for faster and cheaper pharmaceutical manufacturing

RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Manufacturing

INEOS Nitriles launches INVIREO - the first bio-based acetonitrile

The company has released INVIERO, an acetonitrile capable of significantly reducing the carbon footprint of manufacturing processes
Subscribe now